Clinical Trial: Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07805863) titled 'Serum MPO-DNA Complexes as a Biomarker of Disease Activity in Systemic Lupus Erythematosus' on Sept. 01.

Brief Summary: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune system dysregulation and inflammation affecting multiple organs. A key mechanism in its development involves the excessive formation and impaired clearance of neutrophil extracellular traps (NETs), which release myeloperoxidase-DNA (MPO-DNA) complexes into the circulation. Although standard laboratory markers like complement proteins (C3, C4) and anti-dsDNA antibodies are routinely used, they often show inconsistent sensitivi...